PHVS — Pharvaris N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1830487 ·
Netherlands
Last close
$33.41
Market Cap
$2.33B
52W High
$33.50
52W Low
$24.95
ADV30
355,037
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -44,272,001 | -39,200,673 | 259,788,041 | 246,957,998 | 23,455,647 |
| Dec 2025 | 0 | — | -47,599,025 | -46,740,853 | 301,454,999 | 291,678,888 | 30,180,665 |
| Sep 2025 | 0 | — | -39,664,499 | -37,137,035 | 338,896,201 | 329,285,629 | 26,655,561 |
| Jun 2025 | 0 | — | -40,373,097 | -45,480,686 | 209,810,326 | 199,571,685 | 25,474,434 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-137,073,634
Investing CF
$-164,619
Financing CF
$160,607,219
CapEx
$-342,172
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.05
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-579,596,307
Inventory
—
Receivables
$4,551,123
ST Investments
—
EBIT TTM
$-169,822,932
Pretax Income TTM
$-173,711,496
Interest Exp TTM
—
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -169,822,932 | -175,699,397 | 301,454,999 | 30,180,665 | — | -137,073,634 |
| Dec 2024 | 0 | -145,688,167 | -134,221,527 | 291,374,765 | 23,614,024 | — | -120,130,191 |
| Dec 2023 | 0 | -96,913,620 | -100,875,068 | 398,694,465 | 14,646,062 | — | -93,049,093 |
| Dec 2022 | 0 | -86,714,608 | -76,332,557 | 167,732,983 | 18,473,953 | — | -67,162,634 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.71
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $30.00 · spot: $33.41 · call volume: 101 · put volume: 51Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TRVI | Trevi Therapeutics, Inc. | $2.32B | $16.37 | — |
| GIFOF | Grifols SA | $2.29B | $8.85 | — |
| MLYS | Mineralys Therapeutics, Inc. | $2.22B | $25.13 | — |
| KLRA | Kailera Therapeutics, Inc. | $2.48B | $19.13 | — |
| PBH | Prestige Consumer Healthcare Inc. | $2.19B | $46.14 | — |
News headlines (Yahoo Finance, 1h cache)
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
2026-06-15 10:50 · Yahoo
Pharvaris Announces Annual General Meeting of Shareholders
2026-06-11 10:50 · Yahoo
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
2026-05-29 10:50 · Yahoo
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
2026-05-19 17:26 · Yahoo
Pharvaris Equity Raise Supports Late Stage HAE Push And Valuation Case
2026-05-14 06:13 · Yahoo
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-12 20:05 · Yahoo
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000
2026-05-11 20:49 · Yahoo
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-05-11 20:15 · Yahoo
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
2026-05-08 10:00 · Yahoo
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next
2026-04-30 00:42 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.